An Open Label Clinical Trial of Imatinib Mesylate (Glivec) in Patients With Moderate to Severe Nephrogenic Systemic Fibrosis

Trial Profile

An Open Label Clinical Trial of Imatinib Mesylate (Glivec) in Patients With Moderate to Severe Nephrogenic Systemic Fibrosis

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Nephrogenic systemic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2015 New source identified and integrated
    • 02 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top